Rein Therapeutics Inc. (RNTX) Stock Score, Valuation & Financial Research

Rein Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RNTX

Rein Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.58. These figures are a research snapshot, not a buy or sell recommendation.

What Rein Therapeutics Inc. does

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Rein Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of novel therapies for orphan pulmonary and fibrosis indications.

Products and services

  • The company is developing LTI-03, a peptide candidate currently in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and preclinical studies. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its drug candidates for clinical use. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting orphan pulmonary and fibrosis indications Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate, LTI-03 Source
  • Need for additional capital to fund operations and clinical development Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RNTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.58
Market capitalization:
16.3M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -49.76M
Free cash flow:
USD -19.36M
Cash:
USD 8.54M
Total debt:
USD 0.00
EPS:
USD -1.83

What stands out

  • Free cash flow is USD -19.36M, negative for the stored period.
  • The balance sheet shows USD 8.54M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.54M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RNTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RNTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RNTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RNTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of RNTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research RNTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.